Skip to main content

Table 1 The clinical characteristics of the patients from whom the high grade serous ovarian carcinoma samples were obtained

From: Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer

Patient Age at diagnosis (Years) Stage Grade Progression free survival (Months) Overall survival (Months) Current status
OV1 59 IV 3 22.8 74.4 Deceased
OV2 64.5 IIIC 3 N/A N/A N/A
OV3 38.3 IV 3 34.1 86.4 Alive
  1. All patients underwent primary debulking surgery for advanced stage ovarian cancer and had optimal cytoreduction. One patient was lost to follow up and therefore recurrence and overall survival data are not available